Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Health care professionals (HCPs) perspectives on treatment and management of light chain (AL) amyloidosis: An international cross-sectional survey study

Jamie Zigterman, Kristen Hsu, Phaedra Johnson et al. Nov 03, 2025 pp. 7493-7493 10.1182/blood-2025-7493

Abstract Introduction: Light chain (AL) amyloidosis is a rare multi-systemic disease where abnormal proteins in plasma cells misfold and cre...

Momelotinib inhibition of JAK/STAT in a mouse JAKV617F myelofibrosis model showed concurrent activation of p-ERK and p-AKT which was reversed by combination therapy using LP-182, a novel MEK/PI3K/mTOR inhibitor

Brian Ross, Youngsoon Jang, Kevin Heist et al. Nov 03, 2025 pp. 4329-4329 10.1182/blood-2025-4329

Abstract Introduction: Most cases of myelofibrosis (MF) arise from constitutive activation of the JAK/STAT signaling pathway in hematopoieti...

Vitamin d and other micronutrients influence prognosis of patients with non-Hodgkin lymphoma (NHL)

Martin Hajek, Marek Trneny, Samuel Hricko et al. Nov 03, 2025 pp. 7089-7089 10.1182/blood-2025-7089

Abstract Introduction: Lymphocytes, including lymphoma cells require many micronutrients to grow and differentiate properly. Vitamin D is on...

Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study

Naveen Pemmaraju, Andrew Kuykendall, Ellen Ritchie et al. Nov 03, 2025 pp. 3810-3810 10.1182/blood-2025-3810

Abstract Background: Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by red blood cell overproduction. In the phase 2 R...

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Jennifer Marvin-Peek, Courtney DiNardo, Sanam Loghavi et al. Nov 03, 2025 pp. 3399-3399 10.1182/blood-2025-3399

Abstract Background ASXL1 mutation (mut) is frequent in myeloid malignancies, and has adverse prognostic implications in AML treated with int...

From deficiency to competency: Strategies to strengthen classical hematology training across the United States

Jacob Schmelz, Usha Perepu Nov 03, 2025 pp. 8218-8218 10.1182/blood-2025-8218

Abstract INTRODUCTION Classical hematology is a critical yet underemphasized component of hematology/oncology fellowship...

Next-day manufactured CD19 CAR-T cells exhibit superior persistence compared to conventional CAR-T therapy in R/R B-ALL

Meng Lv, Xu-Ying Pei, Yan-Ping Ding et al. Nov 03, 2025 pp. 2407-2407 10.1182/blood-2025-2407

Abstract Introduction: Conventional CD19-directed CAR-T manufacturing requires 7–14 days, potentially delaying treatment and promoting T-cel...

NLRP3 inflammasome inhibition fails to prevent red blood cell lysis in PNH

Nikhil Ranjan, Michael Cole, Gloria Gerber et al. Nov 03, 2025 pp. 2895-2895 10.1182/blood-2025-2895

Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated red blood cell (RBC) lysis due to a...

Artificial intelligence accelerates the identification of measurable residual multiple myeloma by flow cytometry

Clarissa Jordan, Matthew Weybright, Dragan Jevremovic et al. Nov 03, 2025 pp. 2224-2224 10.1182/blood-2025-2224

Abstract Background: Flow cytometry (FC) is widely utilized for the identification of measurable residual disease (MRD) in multiple myeloma...

Clinical impact and prognostic implications of concurrent light-chain amyloidosis in patients with POEMS syndrome: A single-center retrospective study

Yuhan Bao, Di Wang, Peiling Zhang et al. Nov 03, 2025 pp. 7502-7502 10.1182/blood-2025-7502

Abstract Background POEMS syndrome is an uncommon multisystem plasma cell disorder characterized by polyneuropathy, organomegaly, endocrinop...

Association between clonal mutations in Acute Myeloid Leukemia and novel fibrinolytic biomarkers

Sahana Shiggaon, Joshua Richman, Ella Johnson et al. Nov 03, 2025 pp. 5252-5252 10.1182/blood-2025-5252

Abstract Introduction: Acute myeloid leukemia (AML) is characterized by dysregulated fibrinolysis, which leads to bleeding and thrombotic co...

Demographic and regional trends in aplastic anemia mortality among adults in the United States, 1999-2020: A retrospective study using CDC wonder data

Jugraj Singh, Hritik Madan, Ahmad Qaisar et al. Nov 03, 2025 pp. 7901-7901 10.1182/blood-2025-7901

Abstract Introduction: Global and historical data identify Aplastic Anemia as a high-risk disease with significant early mortality. Factors...

Outcomes of patients with Richter transformation (RT) treated with frontline chemoimmunotherapy (CIT) and BTK inhibitor (BTKi)

Sirui Ma, Weiyun Ai, Carrie Ho et al. Nov 03, 2025 pp. 2110-2110 10.1182/blood-2025-2110

Abstract Background: Despite a typically indolent course observed in chronic lymphocytic leukemia (CLL), 2-8% of patients will develop an ag...

In Vivo transfer of CD4+ T cells reshapes CD8+ T cell differentiation trajectory in humans

Andrew McIntyre, Maria Cuadrado, Joshua Hughes et al. Nov 03, 2025 pp. 260-260 10.1182/blood-2025-260

Abstract Relative to donor CD8+ T cells, the recovery of CD4+ T cell populations is severely delayed following allogeneic hematopoietic stem...

EASIX-guided risk stratification of severe coagulopathy and early mortality among newly diagnosed acute myeloid leukaemia with APL-like phenotype

Mingkai Shu, Wenjing Ding, Xiaoli Li et al. Nov 03, 2025 pp. 1303-1303 10.1182/blood-2025-1303

Abstract Introduction: Acute promyelocytic leukemia (APL)-like is a unique subgroup of non-M3 acute myeloid leukemia (AML), with a special C...

Optimizing outcomes and accessibility of matched sibling donor transplantation for severe hemoglobinopathies in low-resource settings

Mohana Reddy, Deepa Trivedi, Vidhi Mayur et al. Nov 03, 2025 pp. 5987-5987 10.1182/blood-2025-5987

Abstract Allogenic HSCT remains the only curative approach for thalassemia major. We describe results of a cost-consciou...

Comparative efficacy of therapeutic interventions for thalassemia-induced osteoporosis: A network meta-analysis

Muhammad Sohaib Asghar, Muhammad Hamza Mushtaq, Syed Muhammad Muneeb Akhtar et al. Nov 03, 2025 pp. 6474-6474 10.1182/blood-2025-6474

Abstract IMPORTANCE Despite advancements in the management of thalassemia major (TM), osteoporosis remains a significant concern among patie...

Reducing premedication use with intravenous iron in the outpatient setting: A quality improvement project

Mark Attilio, Tara Rakiewicz, Liam Heneghan et al. Nov 03, 2025 pp. 4457-4457 10.1182/blood-2025-4457

Abstract Background: Early formulations of intravenous (IV) iron were associated with anaphylaxis and have since been removed from the marke...

An open-label, multi-center Phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma

Yosra Aljawai, Ah-Reum Jeong, Muthalagu Ramanathan et al. Nov 03, 2025 pp. 1050-1050 10.1182/blood-2025-1050

Abstract Background and Significance Autologous hematopoietic cell transplant (AHCT) is standard of care for multiple myeloma (MM) treatment...

The importance of autologous stem cell transplant (ASCT) in multiple myeloma treatment in the lack of novel therapies

Natalia Cristina Rojas Guerrero, João Nunes, Eduardo Munhoz et al. Nov 03, 2025 pp. 6365-6365 10.1182/blood-2025-6365

Abstract Background: Multiple Myeloma (MM) is an incurable disease; however, its management has evolved significantly in...

Radiotherapy consolidation post-autologous stem cell transplant in Relapsed/Refractory aggressive non-Hodgkin lymphoma improves progression-free and overall survival in patients with partial but not complete metabolic response pre-transplant

Joshua Yi, Chathuri Abeyakoon, David Hodgson et al. Nov 03, 2025 pp. 7188-7188 10.1182/blood-2025-7188

Abstract Background: Salvage chemotherapy followed by autologous stem cell transplant (ASCT) is a potentially curative procedure for patient...

Simplified frailty score for patients with multiple myeloma undergoing autologous stem cell transplant

Chelby Wakefield, Denai Milton, Mark Tanner et al. Nov 03, 2025 pp. 3987-3987 10.1182/blood-2025-3987

Abstract Background: Autologous stem cell transplant (autoHCT) is standard of care for eligible patients with newly diagnosed multiple myelom...

Venetoclax plus mitoxantrone hydrochloride liposome and Azacitidine As first-line treatment for adults with Acute Myeloid Leukemia

Zhuo Wan, Dian Lou, Jingyu Hu et al. Nov 03, 2025 pp. 3456-3456 10.1182/blood-2025-3456

Abstract Background The standard “3+7” regimen (idarubicin/daunorubicin combined with cytarabine, IA/DA) remains the cornerstone of first-lin...

Prophylactic G-CSF (granulocyte colony-stimulating factor) in AML (Acute myeloid leukemia) induction: A meta-analysis dispelling relapse concerns and reinforcing supportive benefit

Anubhuti Sharma, Arundhati Sharma, Simranpreet Singh Daid et al. Nov 03, 2025 pp. 6984-6984 10.1182/blood-2025-6984

Abstract Introduction: Granulocyte colony-stimulating factor (G-CSF) is routinely used to reduce chemotherapy-induced ne...

Zanubrutinib combined with anti-CD19 CAR-T cell therapy in relapsed and refractory B-cell lymphoma

Xiangmin Wang, Qing Zhang, Yujie Li et al. Nov 03, 2025 pp. 7233-7233 10.1182/blood-2025-7233

Abstract Background The response rate and long-term survival of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page